Discovery of Inhibitors of Membrane Traffic from a Panel of Clinically Effective Anticancer Drugs

Biological & Pharmaceutical Bulletin
Hiroko KamataTakao Yamori

Abstract

In addition to their major targets, clinically effective drugs may have unknown off-targets. By identifying such off-targets it may be possible to repurpose approved drugs for new indications. We are interested in the Golgi apparatus as a novel target for cancer therapy, but there is a paucity of candidate Golgi-disrupting drugs. Here, we aimed to identify Golgi-disrupting compounds from a panel of 34 approved anticancer drugs by using HBC-4 human breast cancer cells and immunofluorescence microscopy to visualize the Golgi apparatus. The screen identified five drugs having Golgi-disrupting activity. Four of them were vinca alkaloids (vinorelbine, vindesine, vincristine and vinblastine), and the fifth drug was eribulin. This is the first study to demonstrate that vinorelbine, vindesine and eribulin possess Golgi-disrupting activity. The 5 drugs are known to inhibit tubulin polymerization and to induce microtubule depolymerization. Interestingly, a microtubule-stabilizer paclitaxel did not induce Golgi-disruption, suggesting that the three-dimensionally preserved microtubules are partly responsible for maintaining the Golgi complex. Concerning eribulin, a noteworthy drug because of its high clinical efficacy against advanced brea...Continue Reading

References

Jul 1, 1985·Experimental Cell Research·J Thyberg, S Moskalewski
Feb 2, 1999·Experimental Cell Research·J Thyberg, S Moskalewski
Mar 19, 1999·European Journal of Cell Biology·C Alvarez, E S Sztul
Feb 18, 2006·The Journal of Biological Chemistry·Jean-Christophe ZeehJacqueline Cherfils
Apr 20, 2006·Journal of the National Cancer Institute·Shin-ichi YaguchiTakao Yamori
May 26, 2006·Nature·Judith S Sebolt-Leopold, Jessie M English
Mar 28, 2008·Expert Opinion on Drug Metabolism & Toxicology·Maria C Shoshan, Stig Linder
Jul 16, 2008·Advances in Cancer Research·Yihai Cao
Jul 23, 2008·Molecular Cancer Therapeutics·Tatiana OkounevaMary Ann Jordan
Jan 8, 2009·Journal of Natural Products·David G I Kingston
Nov 18, 2011·Expert Opinion on Pharmacotherapy·Carole GourmelonMario Campone
Dec 30, 2011·Current Medicinal Chemistry·T AiL Chen
Apr 21, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ali McBride, Sara K Butler
Mar 16, 2013·Molecular BioSystems·Zikai WuLuonan Chen
Mar 29, 2014·Expert Opinion on Investigational Drugs·Komal JhaveriGabriela Chiosis
Nov 9, 2014·Breast Cancer Research and Treatment·Chris TwelvesAhmad Awada
Apr 4, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicholas F Dybdal-HargreavesSusan L Mooberry
Oct 1, 2016·Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology·Jonathan NoujaimRobin Lewis Jones
Nov 2, 2016·Journal of Cell Science·Cinzia Progida, Oddmund Bakke
Mar 4, 2017·European Journal of Cell Biology·Uma Saimani, Kyoungtae Kim
Mar 25, 2018·Trends in Cell Biology·Maud Martin, Anna Akhmanova

❮ Previous
Next ❯

Citations

Oct 15, 2020·Neurotoxicology·Gui-Zhou LiJing Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Related Papers

Gan to kagaku ryoho. Cancer & chemotherapy
K Fukuoka, N Saijo
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Kate Traynor
Cancer Chemotherapy and Pharmacology
Leslie S KurtzbergBeverly A Teicher
Current Oncology Reports
Neeraj R AgrawalTarek Mekhail
© 2022 Meta ULC. All rights reserved